In terms of surface antigen, presentations of major histocompatibility complex (MHC) independent, CAR‐based therapies have been used successfully against relevant tumors; however, engineered TCR T cells can identify tumor cells via the MHC complex, the antigenic peptides present on their surface. Here, HLA-C is linked to neoplasm.